Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4
- PMID: 21775649
- DOI: 10.1152/ajpregu.00424.2010
Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4
Abstract
The aim of our study was to investigate the anorectic and brain stimulatory effects of various doses of exendin-4 (Ex-4) and to investigate the role of the vagus nerve in Ex-4-induced brain activation. A dose-related increase in c-fos mRNA expression was observed following Ex-4 administration (0.155-15.5 μg/kg). Doses of Ex-4 that caused anorexia without aversive effects (0.155, 0.775 μg/kg) induced c-fos expression in the hypothalamic arcuate and paraventricular (PVH; parvocellular) nuclei as well as in the limbic and brainstem structures. Doses of Ex-4 that caused aversion (1.55, 15.5 μg/kg) stimulated the same regions (in a more intense way) and additionally activated the magnocellular hypothalamic structures (supraoptic nucleus and PVH magnocellular). The brain c-fos pattern induced by Ex-4 showed both similarities and differences with that induced by refeeding. Subdiaphragmatic vagotomy significantly blunted the stimulation of c-fos mRNA expression induced by Ex-4 in the nodose ganglion, the medial part of nucleus of the solitary tract, and the parvocellular division of the PVH. Pretreatment with Ex-9-39 (330 μg/kg ip) impaired the neuronal activation evoked by Ex-4 in all brain regions and in the nodose ganglion. Effects of Ex-4 on hypothalamic-pituitary-adrenal axis activity were not altered by vagotomy. Results of this study demonstrate and relate the anorectic and brain stimulatory effects of aversive and nonaversive doses of Ex-4 and indicate that the activation of specific central regions induced by the peripheral administration of Ex-4 is, at least in part, dependent on the integrity of the vagus nerve.
Similar articles
-
Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat.Endocrinology. 1997 Oct;138(10):4445-55. doi: 10.1210/endo.138.10.5270. Endocrinology. 1997. PMID: 9322962
-
Acute glucocorticoid pretreatment suppresses stress-induced hypothalamic-pituitary-adrenal axis hormone secretion and expression of corticotropin-releasing hormone hnRNA but does not affect c-fos mRNA or fos protein expression in the paraventricular nucleus of the hypothalamus.J Neuroendocrinol. 2003 Nov;15(11):1075-83. doi: 10.1046/j.1365-2826.2003.01100.x. J Neuroendocrinol. 2003. PMID: 14622438
-
Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro.Endocrinology. 2012 May;153(5):2208-22. doi: 10.1210/en.2011-1795. Epub 2012 Feb 14. Endocrinology. 2012. PMID: 22334721
-
Corticotropin-releasing hormone and the sympathoadrenal system are major mediators in the effects of peripherally administered exendin-4 on the hypothalamic-pituitary-adrenal axis of male rats.Endocrinology. 2014 Jul;155(7):2511-23. doi: 10.1210/en.2013-1718. Epub 2014 Apr 14. Endocrinology. 2014. PMID: 24731096
-
A physiological role for adrenomedullin in rats; a potent hypotensive peptide in the hypothalamo-neurohypophysial system.Exp Physiol. 2000 Mar;85 Spec No:163S-169S. doi: 10.1111/j.1469-445x.2000.tb00020.x. Exp Physiol. 2000. PMID: 10795919 Review.
Cited by
-
Impact of short and long exposure to cafeteria diet on food intake and white adipose tissue lipolysis mediated by glucagon-like peptide 1 receptor.Front Endocrinol (Lausanne). 2023 May 24;14:1164047. doi: 10.3389/fendo.2023.1164047. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37293487 Free PMC article.
-
The Effect of the Sodium-Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer's Disease.Biomedicines. 2023 Mar 27;11(4):1025. doi: 10.3390/biomedicines11041025. Biomedicines. 2023. PMID: 37189641 Free PMC article.
-
Activation of glucagon-like peptide-1 receptors reduces the acquisition of aggression-like behaviors in male mice.Transl Psychiatry. 2022 Oct 13;12(1):445. doi: 10.1038/s41398-022-02209-0. Transl Psychiatry. 2022. PMID: 36229445 Free PMC article.
-
Semaglutide for the treatment of obesity.Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21. Trends Cardiovasc Med. 2023. PMID: 34942372 Free PMC article. Review.
-
GLP-1 physiology informs the pharmacotherapy of obesity.Mol Metab. 2022 Mar;57:101351. doi: 10.1016/j.molmet.2021.101351. Epub 2021 Oct 6. Mol Metab. 2022. PMID: 34626851 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources